Denali Therapeutics (NASDAQ:DNLI) Stock Keeps Buy Rating at BTIG Research

BTIG Research reaffirmed their buy rating on shares of Denali Therapeutics (NASDAQ:DNLI) in a research report sent to investors on Wednesday,Benzinga reports. The firm currently has a $39.00 price objective on the stock.

Several other research firms also recently commented on DNLI. Wedbush reissued an “outperform” rating and issued a $26.00 price objective on shares of Denali Therapeutics in a report on Monday, July 13th. Morgan Stanley boosted their target price on shares of Denali Therapeutics from $35.00 to $36.00 and gave the stock an “overweight” rating in a report on Thursday, July 23rd. UBS Group boosted their target price on shares of Denali Therapeutics from $25.00 to $34.00 and gave the stock a “buy” rating in a report on Friday, August 7th. B. Riley Financial upped their price target on shares of Denali Therapeutics from $30.00 to $35.00 and gave the stock a “buy” rating in a research report on Tuesday, August 25th. Finally, Wall Street Zen upgraded shares of Denali Therapeutics from a “sell” rating to a “hold” rating in a research note on Saturday, October 24th. Thirteen research analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has given a Sell rating to the company. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus price target of $36.15.

Denali Therapeutics Stock Performance

Shares of NASDAQ DNLI opened at $20.96 on Wednesday. The company has a debt-to-equity ratio of 0.01, a quick ratio of 8.32 and a current ratio of 8.37. The stock has a 50 day moving average price of $20.35 and a 200 day moving average price of $21.25. The stock has a market capitalization of $3.35 billion, a PE ratio of -12.12 and a beta of 1.08. Denali Therapeutics has a 52 week low of $13.75 and a 52 week high of $27.30.

Denali Therapeutics (NASDAQ:DNLI) last posted its quarterly earnings results on Tuesday, November 3rd. The company reported $0.37 earnings per share for the quarter, topping the consensus estimate of ($0.27) by $0.64. The company had revenue of $17.78 million for the quarter, compared to analyst estimates of $12.67 million. During the same period last year, the firm earned ($0.74) EPS. Analysts predict that Denali Therapeutics will post -2.70 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other Denali Therapeutics news, insider Alexander O. Schuth sold 2,857 shares of the company’s stock in a transaction that occurred on Tuesday, August 11th. The stock was sold at an average price of $25.07, for a total value of $71,624.99. Following the sale, the insider owned 281,763 shares in the company, valued at $7,063,798.41. This represents a 1.00% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. 9.70% of the stock is currently owned by company insiders.

Institutional Trading of Denali Therapeutics

A number of hedge funds have recently made changes to their positions in the business. Mitsubishi UFJ Asset Management Co. Ltd. acquired a new stake in Denali Therapeutics during the 2nd quarter valued at $26,000. Global Retirement Partners LLC bought a new position in Denali Therapeutics during the second quarter worth $28,000. Nykredit A S acquired a new position in shares of Denali Therapeutics in the second quarter valued at $38,000. Allworth Financial LP acquired a new position in shares of Denali Therapeutics in the second quarter valued at $47,000. Finally, Manchester Capital Management LLC increased its holdings in shares of Denali Therapeutics by 5,505.6% in the third quarter. Manchester Capital Management LLC now owns 2,018 shares of the company’s stock valued at $42,000 after purchasing an additional 1,982 shares during the last quarter. 92.92% of the stock is owned by institutional investors and hedge funds.

Key Headlines Impacting Denali Therapeutics

Here are the key news stories impacting Denali Therapeutics this week:

• Positive Sentiment: AVLAYAH sales and Q4 outlook: Net product revenue reached $17.8 million in the second full commercial quarter. Denali expects Q4 2026 product revenue of $30 million to $32 million, signaling substantial near-term growth. Denali Q3 2026 financial results and business highlights
• Positive Sentiment: Revenue beat estimates: Q3 revenue of $17.78 million topped analyst expectations of $12.67 million. The company also reported a $70.1 million net income for the quarter. Denali Therapeutics soars on earnings beat
• Positive Sentiment: Analyst targets raised: Morgan Stanley lifted its target to $42 and maintained Overweight; Wedbush raised its target to $24 and maintained Outperform. BTIG reaffirmed Buy with a $39 target. The higher targets reflect analyst optimism, though they are not guarantees of future performance. Read More., Read More., Read More.
• Positive Sentiment: Pipeline and balance sheet: Denali said a 2027 BLA filing for zafinofusp is on track and expects data from five TransportVehicle programs in 2027. Cash, equivalents and marketable securities totaled $1.0 billion. Denali Q3 2026 financial results and business highlights
• Neutral Sentiment: Earnings quality context: Q3 net income included a one-time $194 million gain from selling a Priority Review Voucher, so the reported profit is not solely reflective of recurring operations. Denali Q3 2026 financial results and business highlights

Denali Therapeutics Company Profile

Denali Therapeutics Inc is a biopharmaceutical company focused on discovering and developing therapies for patients with neurodegenerative diseases. The company’s research programs target conditions including Parkinson’s disease, Alzheimer’s disease, amyotrophic lateral sclerosis, and lysosomal storage disorders.

Denali uses its blood-brain barrier transport technology, known as the Transport Vehicle platform, to design medicines intended to deliver therapeutic proteins and other biologic treatments into the central nervous system.